<DOC>
	<DOCNO>NCT00007813</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy use kill tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : This phase I trial study side effect best dose cyclophosphamide give together combination chemotherapy peripheral stem cell transplant treat patient malignant solid tumor .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation Plus Chemotherapy Treating Patients With Malignant Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether autologous transplantation mobilize CD34+ peripheral blood stem cell ( PBSC ) provide complete hematologic reconstitution myeloablative chemotherapy comprise etoposide ( VP-16 ) carboplatin ( CBDCA ) patient metastatic recurrent rhabdomyosarcoma , neuroblastoma , Ewing 's sarcoma/primitive neuroectodermal tumor , germ cell tumor , childhood brain tumor , hepatoblastoma . - Determine frequency yield CD34+ PBSC granulocyte-macrophage colony-forming unit ( GM-CFU ) mobilize , harvest , purify single prim course high-dose cyclophosphamide ( CTX ) follow filgrastim ( G-CSF ) . - Correlate number CD34+ cell GM-CFU autologous PBSC graft time engraftment white blood cell , neutrophil , platelet patient . - Determine optimal day PBSC harvest single prim course high-dose CTX G-CSF patient . - Determine whether CD34+ PBSC rescue daily post-transplantation G-CSF decrease time hematopoietic recovery high-dose VP-16 CBDCA compare historical result achieve similar patient rescue bone marrow . - Compare tumor cell content marrow , mobilize blood , purify CD34+ PBSC graft preparation . - Determine optimal timing PBSC mobilization harvest relation extent prior chemotherapy patient . - Determine feasibility single leukapheresis PBSC harvest child . - Determine toxic effect regimen patient . - Determine antitumor activity regimen patient . OUTLINE : This dose-escalation study cyclophosphamide . Mobilization/harvest : Patients receive cyclophosphamide IV 90 minute day 0 filgrastim ( G-CSF ) subcutaneously IV 30 minute day 2-15 blood count recover . Peripheral blood stem cell ( PBSC ) harvest select CD34+ cell day 15 . Bone marrow also harvest case insufficient PBSC harvest . Preparative regimen/transplantation : Patients receive carboplatin IV 1 hour etoposide IV continuously day -6 -4 . Cyclophosphamide administer IV 1 hour day -3 -2 IV continuously day -3 -2 , -4 -2 , -5 -2 , -6 -2 . PBSC bone marrow reinfused day 0 . Cohorts 3-10 patient receive escalate dos cyclophosphamide maximum tolerate dose ( MTD ) determine . The MTD define high dose 20 % patient experience dose-limiting toxicity . At least 6 additional patient receive cyclophosphamide MTD . PROJECTED ACCRUAL : A minimum 36 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove malignant solid tumor , include follow : Rhabdomyosarcoma Neuroblastoma Ewing 's sarcoma/primitive neuroectodermal tumor Germ cell tumor Childhood brain tumor Hepatoblastoma Metastatic disease OR fail least firstline therapy Ineligible high priority protocols PATIENT CHARACTERISTICS : Age : Under 36 transplantation Performance status : Karnofsky 60100 % Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count least 1,000/mm3 Platelet count least 75,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Liver function test great 2 time normal OR No active hepatitis liver biopsy No hepatitis B infection Renal : Creatinine great 1.5 mg/dL OR Glomerular filtration rate ( preferably measure ) great 60 % normal Cardiovascular : Left ventricular ejection fraction least 45 % No active congestive heart failure No active arrhythmia Pulmonary : Age 8 : clinically normal pulmonary function Over age 8 : FEV1 FVC least 50 % predict Arterial blood gas normal DLCO least 50 % spirogram difficult interpret due poor patient effort , recent surgery , pulmonary tumor involvement Other : No mucositis mucosal infection prior myeloablative chemotherapy HIV negative Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>stage IV childhood liver cancer</keyword>
	<keyword>recurrent childhood liver cancer</keyword>
	<keyword>childhood hepatoblastoma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>childhood germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>extragonadal germ cell tumor</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>childhood teratoma</keyword>
	<keyword>childhood malignant testicular germ cell tumor</keyword>
	<keyword>childhood malignant ovarian germ cell tumor</keyword>
	<keyword>childhood extragonadal germ cell tumor</keyword>
	<keyword>recurrent childhood malignant germ cell tumor</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
</DOC>